Europe • Frankfurt Stock Exchange • FRA:IDP • US09062X1037
We assign a fundamental rating of 6 out of 10 to IDP. IDP was compared to 84 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making IDP a very profitable company, without any liquidiy or solvency issues. IDP is valued quite cheap, but it does not seem to be growing. With these ratings, IDP could be worth investigating further for value investing!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.51% | ||
| ROE | 8.84% | ||
| ROIC | 9.7% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 28.5% | ||
| PM (TTM) | 15.98% | ||
| GM | 75.24% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | 2.78 | ||
| Altman-Z | 3.31 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.72 | ||
| Quick Ratio | 2.04 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.62 | ||
| Fwd PE | 11.5 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.52 | ||
| EV/EBITDA | 7.79 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.
ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.
BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.
The financial health rating of BIOGEN INC (IDP.DE) is 7 / 10.
The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to decline by -7.36% in the next year.